Human T-lymphotropic virus type 1 (HTLV-1) is a human retrovirus that preferentially infects CD4+ lymphocytes in vivo. The virus causes a hematological malignancy known as adult T-cell leukemia, and an inflammatory disease in the central nervous system (CNS) called HTLV-1-associated myelopathy/ tropical spastic paraparesis (HAM/TSP). Approximately 0.3% of HTLV-1-infected individuals develop HAM/TSP. HAM/TSP patients show spastic paraparesis and sphincter dysfunction, as well as sensory disturbance of the lower extremities, which corresponds to pathological lesions in the spinal cord. Although the majority of HAM/TSP patients progress slowly, this disease progresses rapidly in some patients. An increased HTLV-1 proviral load is more common in HAM/TSP patients than in asymptomatic HTLV-1 carriers, and is considered to be a strong risk factor for HAM/TSP development. A prominent cellular immune response in HAM/TSP patients is a significantly elevated number of HTLV-1 Tax-specific CD8+ cytotoxic T lymphocytes (CTL) in peripheral blood mononuclear cells compared with asymptomatic HTLV-1 carriers. Additionally, CD4+ and CD8+ lymphocytes accumulate in the perivascular areas of spinal cords in HAM/TSP patients. Viral DNA, mRNA and proteins are detected only in infiltrating CD4+ T cells, but not in neural cells. A high proportion of HTLV-1-specific CTL infiltrates the CNS. Furthermore, some neural cells surrounding the CTL, predominantly oligodendrocytes, undergo apoptosis. These findings suggest the pathogenesis that the HTLV-1-specific inflammation induced by the interaction of HTLV-1-infected CD4+ T cells and HTLV-1-specific CD8+ CTL causes bystander damage in the CNS. In the present review, a more exact pathogenesis of HAM/TSP is discussed based on virology, immunology and neuropathology.
Introduction
Human T-lymphotropic virus type 1 (HTLV-1) is a human retrovirus that preferentially and persistently infects CD4+ lymphocytes in vivo.
1 HTLV-1 is estimated to infect 5-10 million people worldwide and 1.08 million in Japan. 2, 3 Though HTLV-1 infection persists for life, just 0.3% of individuals infected with this virus develop the neurological disease termed HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), whereas 5% develop the hematological malignancy known as adult T-cell leukemia (ATL). [4] [5] [6] Other HTLV-1-associated diseases include HTLV-1-associated uveitis, and several inflammatory diseases in the lungs, muscles and joints. [7] [8] [9] [10] The vast majority of HTLV-1-infected individuals remain in an asymptomatic HTLV-1 carrier (AC) state. HAM/TSP is an inflammatory disease of the spinal cord, and patients with this disease show spastic paraparesis and sphincter dysfunction, as well as sensory disturbance of the lower extremities, which is consistent with the corresponding pathological alterations in the spinal cord. 11, 12 This disease progresses slowly in the majority of HAM/TSP patients; however, in some patients, it progresses rapidly. 13, 14 HTLV-1 virology HTLV-1 encodes two long terminal repeats along with the gag, pol and env genes. It also encodes an additional gene called pX, which is translated into Tax and Rex. 15 The Tax protein directly activates HTLV-1 through a long terminal repeat, resulting in viral expression. 16 It also transactivates many cellular genes, such as interleukin (IL)-2, IL-2Ra, IL-6, vascular cell adhesion molecule 1 (VCAM-1) and granulocyte macrophage colony-stimulating factor (GM-CSF), through the nuclear factor-jB signaling pathway. 17 Additionally, Tax upregulates the expression of molecules, such as OX40, stromal cellderived factor-1, major histocompatibility complex (MHC) class I, C-X-C motif chemokine 10 (CXCL10), macrophage inflammatory proteins-1a and b, and c-fos through other signal transduction pathways, and some of these molecules result in the proliferation of HTLV-1-infected cells. 18 The same mRNA that encodes the Tax protein also encodes the Rex protein when it is differently spliced. The Rex protein suppresses viral RNA splicing, resulting in a downregulation of Tax/Rex expression. 19 This modulation of viral RNA expression ultimately inhibits Tax-induced transcription. Positive-strand viral genes encode these proteins.
Recently, a new viral gene, named HTLV-1 basic zipper factor (HBZ), was discovered to be encoded by the negative-strand of the HTLV-1 genome. 20 The HBZ protein contains an N-terminal transcriptional activation domain and a leucine zipper motif at the C-terminus. The HBZ protein binds to JUN, JUNB and JUND, and leads to regulation of the AP-1 signaling pathway. 21 HBZ has been found to inhibit Tax-mediated transactivation through binding to CREB2. 22 Unlike Tax mRNA, which is detected in approximately 40% of ATL patients, HBZ mRNA is constitutively expressed in all ATL patients.
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Properties of HTLV-1-infected cells 
HTLV-1 transmission
Transmission of HTLV-1 occurs through HTLV-1-infected cells-containing body fluids, such as blood, semen and breast milk, rather than by direct infection with the virus particles. The major routes of primary infection are sexual transmission, blood transfusion and mother-to-child transmission through breast milk. 32 Mother-to-child transmission occurs in the intestine mucosa after ingestion of HTLV-1-infected cells in the milk. Three models of cell-to-cell infection have been proposed, including virological synapses, cellular conduits (transient membrane extensions) and viral biofilms (extracellular viral assemblies). [33] [34] [35] A recent study has shown that dendritic cells capture viral particles on the cell surface and pass them onto uninfected T cells. 36 It is still unclear which transmission mode dominates in HTLV-1 infection in vivo. The envelope protein is responsible for the attachment and entry of viral particles to the cells. Three HTLV-1 receptors have been reported as being used for infection of viral particles. HTLV-1 binds heparan sulfate proteoglycans on the target cell, and neuropilin-1 and glucose transporter 1 act synergically for the binding and fusion of viruses to the cells. [37] [38] [39] The virus then enters the cytoplasm, where the viral RNA is transcribed into dsDNA and integrated into the host genome. This state is described as a provirus. When the infected cells split during the cell cycle (clonal expansion), the provirus is also replicated and included in the daughter cells. Thus, HTLV-1 spreads within an infected individual by two ways: mitosis of HTLV-1-infected cells and direct cell-to-cell infection. Although cell-to-cell infection is known to occur during primary transmission, it has not been clarified to what extent the cell-to-cell infection affects the spread of the virus in the body of HTLV-1-infected individuals after primary viral transmission.
HTLV-1 integration site and clonal expansion of HTLV-1-infected cells
Because <5% of HTLV-1-infected individuals develop ATL or HAM/TSP, it was speculated that the particular integration site of the virus might affect the development of these diseases in AC. Gillet et al. developed a new high-throughput technology to determine the integration site and clonality of HTLV-1-infected cells. 40 Their method showed that HTLV-1 does not have specific integration sites in infected individuals, including AC and patients with HAM/TSP or ATL. Many HTLV-1-infected T-cell clones were detected in HAM/TSP patients, showing that these cells are more abundant than previously believed. Further analysis showed that HTLV-1 is preferentially integrated near the site of the transcriptionally active regions of the genome, causing clonal expansion of the infected cell. 41 These findings suggest that HTLV-1-infected cells that have the virus integrated at sites near these genes acquire the advantage of clonal expansion, and are detected by this technique. HAM/TSP patients show a high proviral load (PVL), and mitosis is thought to play a significant role in the increase in PVL. However, it is unknown what degree of the PVL is derived from mitosis and what degree is as a result of cell-tocell infection or whether this proportion fluctuates during the clinical course of the disease. Further studies are required to determine how mitosis and cell-to-cell infection affect the increase in PVL, because this information could lead to new therapeutic methods for eliminating viruses in HTLV-1-infected individuals.
Increased HTLV-1 PVL in HAM/TSP HAM/TSP patients show an average HTLV-1 PVL of 7.9% in PBMC, whereas AC have an average of 1.2%. 42 HAM/TSP patients typically show PVL that are approximately sixfold higher than those of AC, and the high PVL is a strong risk factor for HAM/ TSP development. Because the PVL of many HAM/ TSP patients overlap with those of AC, HAM/TSP patients cannot be distinguished from AC using these values. When the HTLV-1 PVL percentage in PBMC exceeds 1%, the risk of developing HAM/ TSP increases exponentially. 42 The clinical status of HAM/TSP patients was parallel to their change in HTLV-1 PVL. 43, 44 Similarly, a case report on a HAM/TSP patient reported that when the patient deteriorated rapidly, her PVL increased from 0.2% to 1.3% in PBMC, and rose from 1.2% to 13.6% in cerebrospinal fluid (CSF) cells.
14 These data suggest that disease progression is associated with an increase in the HTLV-1 PVL. Southern blotting of HTLV-1 provirus shows that HAM/TSP patients and their family members have clonally expanded HTLV-1-infected cells. 45 Clonal integration of HTLV-1 was detected by Southern blotting in 19% of PBMC from HAM/TSP patients. Surprisingly, family members of HAM/TSP patients, who were asymptomatic HTLV-1 carriers, also had an increased PVL, and 16% of them had clonal integration of HTLV-1, but lacked symptoms of hematological malignancy. No clonal integration was observed in AC in non-HAM/TSP families. Despite the increase in PVL, it was difficult to detect HTLV-1 tax mRNA or its protein in fresh PBMC from HAM/TSP patients by using conventional techniques. The reason for the absence of viral expression in vivo is not yet understood, but it might be due to viral latency, presumably resulting from regulation through Tax/Rex/HBZ, or to an immune selection in which HTLV-1-specific cytotoxic T lymphocyte (CTL) might eliminate cells expressing viral proteins.
Viral and host factors related to the risk of HAM/ TSP
Viral factors for the development of HAM/TSP Because HTLV-1 causes two different diseases, ATL and HAM/TSP, early HAM/TSP research speculated that the viruses causing these diseases were different strains. However, intensive sequencing studies using PBMC from ATL and HAM/TSP patients showed that no mutation could be specifically associated with either ATL or HAM/TSP. 46, 47 HTLV-1 has several subtypes, with transcontinental subtype (tax A subtype) and Japanese subtype (tax B subtype) being the main subtypes in Japan. A detailed analysis showed that HAM/TSP patients have a higher proportion of transcontinental subtype compared with AC. 48 The odds ratio for developing HAM/TSP of the transcontinental subtype to the Japanese subtype is 2.46. Despite enthusiastic efforts, viral genomic mutations that can distinguish HAM/TSP patients from AC have not been reported.
Host genetic factors for the development of HAM/TSP
As HAM/TSP occurs in a small subset of HTLV-1-infected individuals, efforts are ongoing to find host genetic factors that affect HAM/TSP development. Human leukocyte antigen (HLA) analyses showed that HLA-A*02 and -Cw*08 are inhibitory factors, whereas HLA-DRB1*0101 and -B*5401 are promoting factors for HAM/TSP. 49, 50 Interestingly, AC with HLA-A*02 show reduced PVL, and HLA-A*02-positive HAM/TSP patients also show a strong cellular immune response to HTLV-1. It is therefore considered that a high immune response associated with HLA-A*02 reduces the number of HTLV-1-infected cells and prevents HAM/TSP development. HLA-DRB1*0101 is associated with CD4+ T cells that recognize HTLV-1 envelope protein in HTLV-1-infected individuals, and HAM/TSP patients with HLA-B*5401 show high PVL. 50, 51 Several other genomic factors that influence HAM/TSP development have also been reported. Inhibitory factors include the single-nucleotide polymorphism (SNP) in the IL-10 promoter 592A allele, the Apa I polymorphism of vitamin D receptor exon 9, the SNP in the IL-15 191C allele, and the 801A mutation in the 3ʹ untranslated region in the stromal cell-derived factor-1. [52] [53] [54] Promoting factors include the SNP in the tumor necrosis factor (TNF)-a promoter 893A allele, the SNP in the Aggrecan variable number tandem repeat 1630 allele and the CA repeat length of the matrix metalloproteinase-9 promoter. [54] [55] [56] The contributions of these genes to the pathogenesis of HAM/TSP are unknown. Nose et al. established a formula containing age, HTLV-1 PVL, HTLV-1 subtype and some of the above factors that were able to identify 88% of HAM/TSP patients in their tested cohort. 57 Immune response to HTLV-1
Immunological abnormalities in HAM/TSP Numerous immunological abnormalities have been reported in HAM/TSP patients. HAM/TSP patients show high antibody titers for HTLV-1 in both their serum and CSF. However, it is impossible to use these titers to distinguish between AC and HAM/TSP patients because of the overlap of their titers. HAM/ TSP patients also have immunoglobulin (Ig)M class antibodies against HTLV-1, but the reason why IgM antibody production continues in chronic infection is unknown. 58 Additionally, activated CD4+ and CD8+ T cells are increased in both the PBMC and CSF in HAM/TSP patients, whereas the number of natural killer cells and natural killer cell activity are each decreased. 59, 60 Recently, it was reported that natural killer T cell activity against HTLV-1 is reduced in HAM/TSP patients. 61 Several HAM/TSP patients show bands of oligoclonal IgG against HTLV-1, as well as an increase in their IgG indexes, suggesting that B-cell responses to HTLV-1 might occur in the CNS. 12 Furthermore, the levels of neopterin secreted by activated macrophages and of CXCL10, both of which are considered to be CSF inflammatory markers, are elevated in the CSF of HAM/TSP patients. [62] [63] [64] In in vitro culture, PBMC from HTLV-1-infected individuals show spontaneous lymphoproliferation in the absence of mitogens or exogenous IL-2. 65 The response is self-limiting; the proliferation of CD4+ and CD8+ T cells peaks in 3-5 days, and disappears within 1 week. 66, 67 This phenomenon is unique to HTLV-1 infection, and the extent of cell proliferation is much greater in HAM/ TSP patients than in AC. HTLV-1-infected cells have little viral protein expression in vivo; however, they produce significant amounts of viral proteins after several hours of culture. Thus, spontaneous lymphoproliferation is considered to include the proliferation of both HTLV-1-infected cells and HTLV-1-specific CTL, which might reflect the phenomena occurring in inflammatory lesions in vivo.
Increased HTLV-1 Tax-specific CTL responses in HAM/ TSP One of the most prominent features of the cellular immune response in HAM/TSP patients is the markedly elevated numbers of HTLV-1 Tax-specific CD8+ CTL in PBMC compared with AC. [68] [69] [70] The epitopes of Tax [11] [12] [13] [14] [15] [16] [17] [18] [19] and Tax 301-309 bind strongly to HLA-A*02:01 and -A*24:02, respectively. [71] [72] [73] Also, the CTL frequency is much higher in the CSF than in PBMC. 74, 75 These CTL produce pro-inflammatory cytokines, including interferon (IFN)-c, TNF-a, and IL-2 and chemokines, such as matrix metalloproteinase-9, on antigen stimulation. 76, 77 It is unknown why HAM/TSP patients show high PVL despite their large number of CTL. Whether or not the CTL frequency correlates with the PVL is controversial. The authors who claimed that the CTL frequency corresponds positively with PVL speculate that increased PVL promote high frequencies of HTLV-1-specific CTL. 78 Whether or not the cytotoxic activity of HTLV-1-specific CTL is different between HAM/TSP patients and AC is also controversial. Several studies have reported that the cytokine production and degranulation activity of CTL are decreased in HAM/ TSP patients when compared with those in AC. 79, 80 However, the work in these reports might have methodological problems. The immune response to antigen stimulation was mainly investigated using flow cytometry in these studies. Notably, after recognition of the antigen, the T-cell receptor and CD3 molecule, as well as CD8 molecule, on the CTL are downregulated, so gating on the antigen-specific CTL is complicated and likely ignores the CTL that actively responded to the antigen. In contrast, a different study that took this difficulty into account reported that no differences were found in the cytokine production and degranulation activity of Taxspecific CTL between HAM/TSP patients and AC. 81 
CTL exhaustion in HAM/TSP
As aforementioned, although the number of HTLV-1-specific CTL is increased in HAM/TSP patients, the PVL remains elevated. Recently, it was shown that in chronic virus infections, such as HIV infection, virus-specific CTL are exhausted by the expression of exhaustion-related molecules, including programmed cell death-1 (PD-1), and T-cell immunoglobulin and mucin domain-containing molecule-3 (Tim-3). 82 HTLV-1-specific CTL of ATL patients express high PD-1 levels, and inhibition of PD-1 by antibodies restores the decreased CTL function. 83 In HAM/TSP patients, it is controversial whether or not HTLV-1-specific CTL are exhausted. Three different groups reported that the PD-1 expression of HTLV-1 Taxspecific CTL is lower in HAM/TSP patients compared with that in AC. 81, 83, 84 Another group claimed that HAM/TSP patients show upregulated PD-1 expression in both their total CD8+ T cells and their Tax-specific CTL based on work using pooled Tax peptides. 80 Additionally, two groups reported that the Tim-3 expression of Tax-specific CTL is downregulated in HAM/TSP patients compared with that in AC. 81, 85 Further studies are required to investigate if the total efficiency, but not the frequency, of HTLV-1 Tax-specific CTL in vivo differs between HAM/TSP patients and AC, and if this contributes to the pathogenesis of HAM/TSP.
Elimination of HTLV-1-infected cells by CTL in vivo
HTLV-1-specifc CTL lines and clones clearly show killing activities in in vitro assays, but it is difficult to show whether or not HTLV-1-specific CTL indeed reduce the number of HTLV-1-infected cells in vivo.
A longitudinal analysis of the CTL response showed that the frequency of CTL was parallel to the change in the HTLV-1 PVL in HAM/TSP patients. 70 Furthermore, the antigen recognition by HTLV-1-specific CTL was degenerated. That is, as the PVL increased, the CTL was able to recognize altered peptide antigens. As HTLV-1 polymerase has a weak proofreading activity, viral mutations frequently occur during replication, resulting in the natural occurrence of variant viruses. 86 Although most of the mutations are not effective for viral replication, several mutations give the virus advantages for viral replication, and the mutations that occur in viral epitopes induce viral escape from CTL. 87 However, CTL with a degenerate T-cell receptor recognition can more efficiently recognize these mutant viruses. A sequencing analysis of the HTLV-I tax gene from HLA-A*02 HAM/TSP patients showed that the epitope amino acids were positively selected by estimating synonymous and non-synonymous changes in viral genes. 88 An analysis of gene expression profiles using microarrays showed that granzymes and perforin, which are cytolytic molecules of CTL, are more highly expressed in HTLV-1-infected individuals with a low PVL. 89 These results suggest that CTL eliminate HTLV-1-infected cells in vivo.
Detection of CTL responses to HBZ
Most CTL studies have focused on the HTLV-1 Taxspecific CTL responses, because these responses are readily detectable in HTLV-1-infected individuals. This sustained activated CTL response to HTLV-1 provides clear evidence of persistent HTLV-1 antigen expression in vivo despite a reduced expression of Tax protein in the circulating HTLV-1-infected cells. Recent studies showed that the expression level of HBZ mRNA is much higher than that of Tax mRNA in both HAM/TSP patients and AC, and this expression is increased in HAM/TSP patients compared with that in AC. 90 Forced HBZ expression in human T cell lines promotes proliferation of the transfected cells, and HBZ transgene expression in CD4+ T cells induces T-cell lymphoma and systemic inflammation in a mouse model. 91 Although HTLV-1 Tax-specific CTL responses have been well studied, little work has been carried out on the frequency or function of HBZ-specific CTL in HAM/TSP patients. Using a combination of epitope prediction and ex vivo peptide-MHC binding assays, MacNamara et al. reported that the individuals with HLA class I alleles that strongly bind HBZ protein had a lower PVL, and that CD8+ T cells specific to HBZ, rather than to the immunodominant protein Tax, are the most efficient at controlling HTLV-1 infection. 92 One study showed that an HBZ epitope was able to induce an HBZ-specific CTL clone from an HLA-A*0201-positive individual in vitro, but these HBZ-specific CTL were scarcely detectable in ATL patients or an AC. 93 Furthermore, the HBZ-specific CTL clone killed significantly fewer HTLV-1-infected cells compared with a Tax-specific CTL clone. 94 There have not been any studies that aimed to determine if other HBZ epitopes exist in humans, nor have there been investigations of whether or not HBZ-specific CTL responses differ between HAM/TSP patients and AC. HBZ mRNA is constitutively expressed in HTLV-1-infected cells in vivo, and HBZ induces the proliferation of these infected cells, thus suggesting that HBZ might be a candidate antigen for cellular immunotherapy for HAM/TSP and ATL patients. 90, 95, 96 For this purpose, it is necessary to identify other HBZ epitopes that induce a strong CTL response in HTLV-1-infected individuals. Therefore, HBZ-specific CTL should be more extensively studied in future experiments.
Immunopathogenesis of HAM/TSP

Neuropathology of HAM/TSP
The macroscopic pathology of HAM/TSP is mild-tosevere atrophy of the spinal cord with a thickening of the leptomeninges, which is dominant at the thoracic level. 97, 98 Myelin pallor is symmetrically observed, mainly in the lateral, anterior and posterior columns. The lateral column is the most extensively involved, whereas the anterior and posterior columns are only marginally affected. Microscopic analysis showed that a considerable number of lymphocytes and foamy macrophages infiltrate the perivascular area, and that the meninges are thickened. Both CD4+ and CD8+ T cells, but preferentially CD8+ T cells, are accumulated around the vessels. 11 Minor amounts of cell infiltration are also scattered in many other areas, including the midbrain, pons, medulla oblongata, cerebellum and cerebral white matter. 99 Patients with long disease durations show hyalinous thickening of the vessel walls. The degree of lymphocyte infiltration decreases as the disease duration increases. 11 The infiltrating lymphocytes produce pro-inflammatory cytokines, such as IFN-c and TNF-a and they express cell adhesion molecules, such as matrix metalloproteinase-9.
100,101 IL-1b is mainly expressed by macrophages and astrocytes, and IFN-c is also expressed by glial cells. HLA class I molecules and b2-microgloblin are expressed on endothelial cells and infiltrating mononuclear cells. Additionally, endothelial cells, microglia and infiltrating mononuclear cells express HLA class II.
Early studies showed HTLV-1 DNA in the CNS of HAM/TSP patients, and therefore some of the infiltrating CD4+ T cells were supposed to be infected with HTLV-1. 102, 103 The key question is if the neural cells also become infected with the virus. A semiquantitative PCR analysis of the HTLV-1 PVL showed that HTLV-1 is detected in DNA extracted from the spinal cord, and that the HTLV-1 DNA amount is decreased in parallel with the disease duration. 103, 104 The PVL correlated with the percentage of infiltrating CD4+ T cells in the examined patients, suggesting that the majority of the HTLV-1-infected cells are CD4+ T cells. Several groups have investigated which cells in the CNS are infected with HTLV-1. An in situ hybridization study detected the HTLV-1 genome without cell type identification. 105 Another study indicated that labeled probes for HTLV-1 were deposited on astrocytes, but the identification was not clear. 106 Using in situ hybridization with high sensitivity, Moritoyo et al. clearly showed that HTLV-1 mRNA is detected only in infiltrating CD4+ T cells, but not in neural cells. 107 Additionally, an in situ PCR study showed that HTLV-1 DNA is detected only in CD4+ T cells in the spinal cord. 108 The in situ PCR technique has a high sensitivity that is able to detect a single copy of HTLV-1 in the tissues as well as a high stringency that minimizes false positive results. Therefore, these findings strongly indicate that no neural cells are infected with HTLV-1 in the spinal cords from HAM/TSP patients. Furthermore, HTLV-1 proteins, including envelope protein, Gag and Tax, have been detected in CD4+ T cells, but these proteins were not observed in neural cells. 109 These data strongly suggest that some of the infiltrating CD4+ T cells are infected with HTLV-1, but the neural cells are not. The neuropathology of HAM/TSP is summarized in Table 1 .
Bystander neural damage in HAM/TSP
Activated HTLV-1-specific CD8+ CTL are markedly increased in the periphery of patients with HAM/TSP. Additionally, abundant CD8+ T cells infiltrate the spinal cord and express the TIA-1 molecule, which is a CTL marker. 104 However, it was unclear if some of these CD8+ T cells were specific for HTLV-1. The exact role of HTLV-1-specific CTL in the pathogenesis of HAM/TSP has been uncertain. Another important question is whether or not HTLV-1-specific CTL infiltrate the CNS and play a role in HAM/TSP pathogenesis. To address this issue, Matsuura et al.
investigated the infiltration of HTLV-1-specific CTL and the expression of HTLV-1 proteins in the spinal cords of HAM/TSP patients. 109 A study using an MHC/Tax tetramer visualized HTLV-1 Tax-specific CTL infiltrating the CNS of HAM/TSP patients. The frequency of HTLV-1 Tax-specific CTL was more than 20% of the CD8+ T cells infiltrating the CNS. Furthermore, HTLV-1 proteins were not detected in the CNS-resident cells, but they were detected in more than 60% of the infiltrating CD4+ T cells. Although neurons were only minorly affected, 36% of CD4+ T cells and some oligodendrocytes underwent apoptosis. Apoptotic oligodendrocytes were frequently in contact with CD8+ T cells, resulting in demyelination of the CNS. These findings suggest the pathogenesis that the immune responses of HTLV-1-specific CTL and HTLV-1-infected CD4+ T cells cause apoptosis in surrounding neural cells (bystander damage; Fig. 1) . 110 To understand how and why uninfected neural cells become apoptotic, it will be necessary to elucidate the underlying mechanism. HTLV-I causes several inflammatory diseases in the eyes, muscles, lungs and joints other than the CNS. CD4+ T cells infected with HTLV-1 circulate in the peripheral blood, and this allows a continuous supply of HTLV CXCL10, and an increased number of cells expressing the counter-receptor CXCR3 in CSF. 111 Immunohistochemistry analysis showed that astrocytes are the primary CXCL10 producers in the spinal cord. An astrocytoma cell line co-cultured with PBMC from HAM/TSP patients produced CXCL10 in response to IFN-c secreted from the CD4+ T cells. In addition, CXCL10 increased the migration activity of the PBMC. The authors speculated that HTLV-1-infected cells in the CNS produce IFN-c, which in turn induces astrocytes to secrete CXCL10. The chemokine then recruits more HTLV-1-infected cells expressing CXCR3, resulting in a positive feedback loop in the CNS. This mechanism is not exclusive to the bystander damage model, but rather, it supports the idea that HTLV-1-infected cells are continuously supplied from the blood circulation to the CNS.
Conclusions
A high HTLV-1 PVL is a strong risk factor for HAM/TSP development. Infiltration of HTLV-1-infected CD4+ T cells into the CNS results in the accumulation of HTLV-1-specific CTL and causes HTLV-1-specific neuroinflammation. More intensive studies to show the dynamic interaction between HTLV-1 and host immune responses in HAM/TSP patients might lead to a more accurate understanding of the disease. Current therapies target inflammatory processes using anti-inflammatory drugs. However, the effect is temporary and not satisfactory. To cure HAM/TSP patients, it will be necessary to develop a radical therapy for eliminating HTLV-1-infected cells.
